US equities
|
NVDA
$237.10
▲+1.35%
SPCX
$165.44
▲+4.08%
MU
$1,059.04
▼-1.48%
TSLA
$376.20
▲+1.51%
MSFT
$527.59
▲+1.94%
INTC
$116.09
▼-2.71%
SNDK
$1,716.52
▼-0.20%
AMD
$627.55
▼-1.00%
NVDA
$237.10
▲+1.35%
SPCX
$165.44
▲+4.08%
MU
$1,059.04
▼-1.48%
TSLA
$376.20
▲+1.51%
MSFT
$527.59
▲+1.94%
INTC
$116.09
▼-2.71%
SNDK
$1,716.52
▼-0.20%
AMD
$627.55
▼-1.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
3.000
+0.120 (+4.17%)
Delayed Quote
Updated: 10:00 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
32
33
Next >
51 Biggest Movers From Thursday
↗
April 18, 2022
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...
Via
Benzinga
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
↗
April 14, 2022
Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
April 14, 2022
Gainers
Via
Benzinga
Why Lexaria Shares Are Rising Today
↗
April 14, 2022
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
April 14, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
April 14, 2022
Via
Investor Brand Network
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
April 14, 2022
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
↗
April 13, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Issues Update on Human Nicotine Study
April 13, 2022
Via
Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program
↗
April 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
April 12, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
April 12, 2022
Via
CannabisNewsWire
Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program
April 12, 2022
Via
Investor Brand Network
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
- Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Aims To Demonstrate DehydraTECH's Performance In Epilepsy Research
↗
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program
April 11, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program
April 11, 2022
Via
CannabisNewsWire
Lexaria (NASDAQ: LEXX) Aims to Demonstrate DehydraTECH’s Performance in Epilepsy Research
April 11, 2022
Via
Investor Brand Network
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
April 11, 2022
KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered...
From
Lexaria Bioscience Corp.
Via
AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program
April 08, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program
April 08, 2022
Via
Investor Brand Network
Lexaria Bioscience's 24th Patent Sets Stage For Market Opportunities In Australia
↗
March 31, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Bioscience’s (NASDAQ: LEXX) 24th Patent Sets Stage for Market Opportunities in Australia
March 31, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia
March 30, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia
March 30, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Optimistic About Upcoming Hypertension Study
↗
March 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Optimistic About Upcoming Hypertension Study
March 28, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study
March 25, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study
March 25, 2022
Via
Investor Brand Network
Lexaria's IP Portfolio Grows Following Receipt Of 24th Granted Patent
↗
March 22, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received a new patent entitled “Compositions...
Via
Benzinga
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
32
33
Next >
